Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Pasithea Therapeutics Corp. Common Stock

KTTA

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Last trade $0.4419
Day change -$0.0581 (-11.62%)
Day range $0.43 – $0.526
Volume 1,810,408
Market cap $18M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$18.38M
Price / earnings
—
Price / book
0.42×
Price / sales
—
EV / sales
—
EV / EBITDA
0.84×

Profitability

Earnings per share
-$0.68
Return on assets
-53.42%
Return on equity
-56.78%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
15.67×
Quick ratio
15.67×
Cash ratio
14.96×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.38M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KTTA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.51M$2.03M$1.93M$7.51M$1.75M$1.66M$1.95M$1.75M
Research and development$4.46M$3.69M$2.94M$2.74M$1.36M$2.15M$1.73M$1.51M
Total operating expenses$6.97M$5.71M$4.88M$10.26M$3.11M$3.81M$3.68M$3.26M
Operating income-$6.97M-$5.71M-$4.88M-$10.26M-$3.11M-$3.81M-$3.68M-$3.26M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$6.58M-$5.27M-$2.87M-$10.11M-$3.04M-$3.72M-$3.56M-$3.18M
Income taxes$0$0$0$0$0$0$0$0
Net income-$6.58M-$5.27M-$2.87M-$10.11M-$3.04M-$3.72M-$3.56M-$3.18M
Net income attributable to common shareholders-$6.58M-$5.27M-$2.87M-$10.11M-$3.04M-$3.72M-$3.56M-$3.18M
EBITDA-$6.5M-$5.87M-$4.72M-$10.1M-$2.61M-$3.96M-$3.52M-$3.1M
Basic earnings per share-$0.20-$0.16-$0.12-$0.79-$0.41-$0.66-$1.61-$2.53
Diluted earnings per share-$0.20-$0.16-$0.12-$0.79-$0.41-$0.66-$1.61-$2.53

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics announced positive Phase 1/1b clinical data for PAS-004, its oral MEK inhibitor candidate, showing substantial reductions in cutaneous neurofibroma size (median 41-46% reduction) and early activity in plexiform neurofibromas across all participants. The drug demonstrated a favorable safety profile with no serious adverse events or treatment-related discontinuations. The FDA has cleared the IND for a Phase 2 randomized, placebo-controlled trial in approximately 200 adults with NF1-associated cutaneous neurofibromas.

GlobeNewswire Inc.

NOTICE TO DISREGARD -- Thea Foundation

THEA, a predictive behavioral AI network focused on risk markets, announced $8 million in financing led by Maven11 Capital. However, the article begins with a retraction notice advising readers to disregard the original news release, creating significant uncertainty about the announcement's validity.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 2, 20241-for-20reverse split